Friday, March 21, 2008

Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model

ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model

PRINCETON, N.J., March 21 /PRNewswire-USNewswire/ -- In a short article published today by the Washington Legal Foundation, US international trade and business lawyer Lawrence Kogan and Russian Government lawyer Yelena Bakulina highlight the common bases in Russian and US history that have triggered new thinking in Russia about how to use privately owned patent rights and cooperative government-university-industry technology transfer arrangements to secure successful market commercialization and peaceful adaptation of publicly-owned bio-warfare technologies.

The article arose from Kogan's June 28, 2007 presentation at a symposium convened by the Vyatka State University, Kirov, Russia, [] as part of a longstanding joint Russian-US cooperative nonproliferation program overseen by the International Science and Technology Center (ISTC), Moscow, Russia. []

According to Bakulina and Kogan, "The [US] federal government['s]...transference of innovation from energy, space, and defense to that of the private sector, and...the American experience in innovation and intellectual property may be advantageous to use in Russia..."

Furthermore as the authors note, "The Kirov Region certainly has the potential to develop effective innovation systems supported by the investment and protection of privately owned intellectual property in the sphere of modern high tech technology. If properly managed...this could create jobs, know-how and other economic and social benefits in the Kirov Region."

"Such an approach," adds Kogan, "would allow Russian biotechnology markets to leapfrog those of the European Union to capture a greater share of the global marketplace for biomedical and bioenvironmental products and processes. Unfortunately, the current EU innovation model is fixated on governmental market control via regulation rather than on market facilitation via economic incentives that ease the burdens and costs of doing business," emphasizes Kogan. "The EU Commission is more obsessed with dictating the rules of the game to ensure 'parity-over-progress' than with providing hi tech European businesses operating in the biotech sectors with
the necessary property rights-based enabling environment and economic freedom to grow and prosper. "Consequently," Kogan notes, "EU biotech and pharma companies have increasingly relocated operations to the US."

The Institute for Trade, Standards and Sustainable Development (ITSSD) is a non-partisan non-profit international legal research and educational organization that examines international law relating to trade, industry and positive sustainable development around the world. This and related ITSSD articles are accessible online at:; and

CONTACT: ITSSD, +1-609-951-2222,

No comments: